REHOVOT, Israel, July 29, 2021 /PRNewswire/ — Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announced today that Ofer Haviv, Evogene’s President and CEO, will present at the Jefferies Virtual Industrials Conference, 2021 taking place on August 3-4,2021. Mr. Haviv’s presentation will focus on Evogene’s disruptive technologies; its tailor-made engines for product discovery and development and its fields of activity through its main subsidiaries and will take place on Tuesday, August 3, 2021, at 09:00 am, EST.
Investors attending the conference who wish to meet with Mr. Haviv, may contact Evogene’s Investor Relations team at ir@evogene.com or through the conference’s online meeting platform.
About Evogene Ltd.:
Evogene (NASDAQ: EVGN) (TASE: EVGN) is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of our broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules and genetic elements. Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd., medical cannabis through Canonic Ltd., ag-biologicals through Lavie Bio Ltd., ag-chemicals through AgPlenus Ltd., and ag-solutions for castor oil production through Casterra Ltd. For more information, please visit www.evogene.com.
|
Evogene Investor Contact: |
US Investor Relations: |
|
Aviva Banczewski/ Rivka Neufeld Investor Relations and Public Relations Manager T: +972-8-931-1940 |
Joseph Green |
|
Laine Yonker Edison Group T: +1 646-653-7035 |
SOURCE Evogene
This news release does not constitute an offer to sell or a solicitation of an…
NEW YORK, July 4, 2025 /PRNewswire/ -- According to a new comprehensive report from The…
Medsien's Advanced Primary Care Management (APCM) program transforms chronic care with fast deployment, smart automation…
Calgary, Alberta--(Newsfile Corp. - July 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE:…
Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions Distinguished experts Dr.…
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="133px" width="400px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="12px" width="12px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="400px" width="1000px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
